Sansure Biotech's (SHA:688289) subsidiary, Zhongshan Sansure Haiji Biopharmaceutical, completed the domestic drug filing for the recombinant human growth hormone injection's workshop at China's National Medical Products Administration, according to a Shanghai Stock Exchange filing on Tuesday.
The Chinese molecular diagnostics and genetic testing products manufacturer will build a new production line in Zhongshan Torch High-Tech Industrial Development Zone, China, for the product after the approval.
The company's shares slipped more than 1% in recent trade.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。